Serologicals Corp., of Atlanta, received U.S. Patent No. 6,743,899 for its purification process, which inactivates infectious prions in its bovine-based Ex-Cyte product.
TranXenoGen Inc., of Shrewsbury, Mass., was issued U.S. Patent No. 6,753,457 covering a method of reprogramming somatic cell nuclei for the production of cloned animals or embryos using nuclear transfer techniques.
ViRexx Medical Corp., of Edmonton, Alberta, received a notice of allowance for a patent titled "Compositions and Methods for Producing Vascular Occlusion," which has broad claims that cover the use of agents that induce site-specific blood clotting based on platelet capture and activation.